Valentina Nekljudova

13PUBLICATIONS
109CO-AUTHORS
Cancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 02, 2025
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Apr 10, 2025
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Feb 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Peter A Fasching, Sabine Schmatloch, Jan Hauke

|Jan 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Fabio Conforti, Valentina Nekljudova, Isabella Sala

|Jan 09, 2025
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial.

Guillermo Villacampa, Alba Llop-Guevara, Natalie Filmann

|Jun 05, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.

Paul Jank, Thomas Karn, Marion van Mackelenbergh

Pageof 3

Frequent Collaborators

13 joint publications

Sibylle Loibl

13 joint publications

Carsten Denkert

11 joint publications

Michael Untch

9 joint publications

Peter Fasching